Marloes J. Van Dongen

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Journal: Nature medicine
Published: January 17, 2026

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

Journal: Cancer treatment reviews
Published: July 24, 2025

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 09, 2025

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2025

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Journal: Nature medicine
Published: February 02, 2024

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Journal: Nature cancer
Published: October 09, 2022

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.

Journal: Gynecologic oncology
Published: November 19, 2021

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Journal: The lancet. Gastroenterology & hepatology
Published: July 20, 2021

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

Journal: Clinical pharmacology and therapeutics
Published: July 13, 2021

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.

Journal: Clinical pharmacokinetics
Published: October 08, 2020

Mathematical modeling of the glucagon challenge test.

Mathematical modeling of the glucagon challenge test.

Journal: Journal of pharmacokinetics and pharmacodynamics
Published: March 24, 2019

Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.

Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.

Journal: Pharmacology research & perspectives
Published: June 17, 2016
Showing 1-12 of 15

Last Updated: 09/26/2026